Perrigo Company PLC produces more than 65bn doses of drugs annually and around 2,000 of those on average are used every second of a day, but it’s the shortage of output by one of its segments, infant formula, slowing its overall results.
Stabilizing the formula business, says CEO Patrick Lockwood-Taylor, is “first and foremost” among “what needs to be done in the short and mid-term as we get this
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?